Bright Minds Biosciences (DRUG) Cash & Equivalents (2020 - 2026)
For the quarter ending Q1 2026, Cash & Equivalents rose 5564.95% year-over-year to $225.8 million, compared with a TTM value of $225.8 million through Mar 2026, up 5564.95%, and an annual FY2025 reading of $60.2 million, up 1336.74% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Cash & Equivalents for 6 consecutive years, with $225.8 million as the latest value for Q1 2026.
- Cash & Equivalents reached $225.8 million in Q1 2026 per DRUG's latest filing, up from $60.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $225.8 million in Q1 2026 and bottomed at $4.0 million in Q1 2025.
- Average Cash & Equivalents over 5 years is $51.4 million, with a median of $7.0 million recorded in 2023.
- Year-over-year, Cash & Equivalents tumbled 43.54% in 2023 and then surged 5564.95% in 2026.
- Bright Minds Biosciences' Cash & Equivalents stood at $8.9 million in 2022, then crashed by 43.54% to $5.0 million in 2023, then decreased by 16.7% to $4.2 million in 2024, then skyrocketed by 1336.74% to $60.2 million in 2025, then soared by 274.86% to $225.8 million in 2026.
- Per Business Quant, the three most recent readings for DRUG's Cash & Equivalents are $225.8 million (Q1 2026), $60.2 million (Q3 2025), and $4.0 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 2.96 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | 225.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 225.83 Mn |
| Dec 31, 2025 | 59.45 Mn |
| Sep 30, 2025 | 60.24 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 38.80 Mn |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 4.93 Mn |
| Mar 31, 2024 | 5.01 Mn |
| Dec 31, 2023 | 4.96 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 8.66 Mn |
| Mar 31, 2023 | 8.60 Mn |
| Dec 31, 2022 | 8.57 Mn |
| Sep 30, 2022 | 8.92 Mn |
| Jun 30, 2022 | 15.50 Mn |
| Mar 31, 2022 | 15.60 Mn |
| Dec 31, 2021 | 15.68 Mn |
| Sep 30, 2021 | 15.70 Mn |
| Jun 30, 2021 | 650,763.97 |
| Mar 31, 2021 | 632,023.20 |
| Dec 31, 2020 | 613,589.27 |
| Sep 30, 2020 | 600,285.66 |